Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Colorectal cancer is an aggressive malignancy with a poor overall outcome. The purpose of
this study is to evaluate the feasibility, safety and efficacy of neoadjuvant oxaliplatin,
irinotecan combined with 5-fluorouraci/leucovorin or S-1 or capecitabine in patients with
resectable colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Chinese Academy of Medical Sciences
Collaborator:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences